KALV 241220 5.00P (KALV241220P5000) Stock Options, News & Quotes

US OptionsDetailed Quotes

KALV241220P5000

Watchlist

0.00
0.000.00%

15min DelayClose Nov 22 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
BusinesswireNov 12 06:30 ET
Needham Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Cuts Target Price to $28
Moomoo NewsNov 4 17:31 ET · Ratings
KalVista Pharmaceuticals: Strategic Financing and Market Potential Drive Buy Rating
TipRanksNov 4 16:35 ET · Ratings
Sector Update: Health Care Stocks Retreat Late Afternoon
MT NewswiresNov 4 15:52 ET
DRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat
MT NewswiresNov 4 08:28 ET
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
BusinesswireNov 4 07:05 ET

Comments

MARKET-TEST-DUMMY

Sep 28 16:37

👀

$KalVista Pharmaceuticals (KALV.US)$

Moomoo AI

Feb 22 12:58

The recent share sale by the CEO and the absence of insider buying over the past year may raise concerns. The low level of insider ownership compared to most companies is also somewhat worrying. Caution is advised when considering buying KalVista Pharmaceuticals stock.

Have KalVista Pharmaceuticals Insiders Been Selling Stock?

Meltyy

Jan 31 14:38

Ph 3 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 3
$Regenxbio (RGNX.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Vertex Pharmaceuticals (VRTX.US)$ Phase 3
$KalVista Pharmaceuticals (KALV.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$Applied Therapeutics (APLT.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3...

JESSE JAMES8832

Jan 28 08:33

could be something brewing here

$KalVista Pharmaceuticals (KALV.US)$

Moomoo AI

Oct 22, 2023 09:04

The termination of the KVD824 trial may impact KalVista's financials and stock price, but the company remains focused on advancing its other drug, sebetralstat, and its oral Factor XIIa inhibitor program for HAE prophylaxis.

KalVista Stock Slumps 37% as KVD824 Trial for Hereditary Angioedema Ended Over Liver Safety Concerns